Pertinax Pharma has appointed Nigel Brooksby as its new chairman, a role that will see him help drive the commercialisation of the company by assisting in corporate strategic and business developments.
During his 38-year career in the pharmaceutical industry, Brooksby has served in roles such from medical sales representative to chairman.
He has held senior appointments in Wellcome – now GSK, Pfizer and as chairman and MD at Sanofi UK and Ireland and as a member of the Sanofi Executive Committee in Europe and America.
Michele Barbour, founder and chief scientific officer, Pertinax Pharma, said: “We are delighted that Nigel has chosen to join our board.
“His unparalleled experience in the pharmaceutical and related industries, his long established industry connections and his experience with early stage biomedical companies make him the ideal individual for the tasks at hand.
“We look forward to Nigel playing a pivotal role in Pertinax Pharma’s continued development as bring the benefits of our patented and commercialised Pertinax technology to the healthcare sector.”